WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014193898) COMBINATION THERAPIES FOR CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/193898    International Application No.:    PCT/US2014/039686
Publication Date: 04.12.2014 International Filing Date: 28.05.2014
IPC:
A61K 31/506 (2006.01), C07D 413/12 (2006.01), A61K 31/519 (2006.01), A61P 35/00 (2006.01)
Applicants: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 (US).
GLAXOSMITHKLINE LLC [US/US]; 2711 Centerville Road Suite 400 Wilmington, Delaware 19808 (US).
HOOS, Axel [DE/US]; (US) (US only).
ORFORD, Keith, W. [US/US]; (US) (US only).
CHUN, Patrick [US/US]; (US) (US only).
SRIRAM, Venkataraman [US/US]; (US) (US only).
PINHEIRO, Elaine, M. [US/US]; (US) (US only).
EBBINGHAUS, Scot, W. [US/US]; (US) (US only)
Inventors: HOOS, Axel; (US).
ORFORD, Keith, W.; (US).
CHUN, Patrick; (US).
SRIRAM, Venkataraman; (US).
PINHEIRO, Elaine, M.; (US).
EBBINGHAUS, Scot, W.; (US)
Common
Representative:
MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 (US)
Priority Data:
61/829,472 31.05.2013 US
61/873,476 04.09.2013 US
61/981,906 21.04.2014 US
Title (EN) COMBINATION THERAPIES FOR CANCER
(FR) THÉRAPIES COMBINÉES CONTRE LE CANCER
Abstract: front page image
(EN)A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a PD-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or immune modulation through PD-1 is beneficial, e.g., cancer.
(FR)L'invention concerne une nouvelle combinaison comprenant un inhibiteur de B-Raf, en particulier le N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-diméthyléthyl)-1,3-thiazol-4-yl]-2-fluorophényl}-2,6-difluorobenzènesulfonamide ou un sel pharmaceutiquement acceptable de celui-ci, l'inhibiteur de MEK, N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phénylamino)6,8-diméthyl;-2,4,7-trioxo-3,4,6,7-tétrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phényl}acétamide, ou un solvate ou un sel pharmaceutiquement acceptable de celui-ci et un antagoniste de PD-1 ; des compositions pharmaceutiques contenant ladite composition ainsi que des méthodes d'utilisation de ces combinaisons et compositions pour le traitement d'états pathologiques où l'inhibition de MEK et/ou de B-Raf et/ou de modulation immunitaire par le biais de PD-1 est bénéfique, par exemple le cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)